Background: Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection.
Introduction
Triple-drug ART has been the cornerstone of HIV treatment since 1996, leading to unprecedented success in disease control in people living with HIV (PLWH). With increasingly potent agents, there has, in recent years, been a drive to investigate treatment simplification strategies that aim to lessen toxicity, drug interactions and cost, through reducing the number of drugs taken.
1,2 Currently available evidence favours dual therapy over monotherapy and is most reassuring in suppressed patients who have maintained virological control for at least 6 months on triple therapy. 3 Dolutegravir and ritonavir-boosted darunavir are both strong players in this paradigm shift, featuring independently in most of the recent dual combinations investigated. 3 They are the agents with the highest potency and barrier to resistance within their respective classes 4-8 and overall; they are therefore also important in salvage therapy for patients experiencing treatment failure and harbouring multi-class drug resistances, when twice-daily dosing is usually recommended. 9,10 Dolutegravir and darunavir/ritonavir have each been paired with lamivudine in dual-therapy studies, with promising data seen in treatment-naive and in virologically suppressed patients alike. [11] [12] [13] [14] [15] [16] Dolutegravir has also been studied in combination with rilpivirine in a combined large randomized, open-label, Phase III trial (SWORD1&2) as well as in smaller cohort studies, showing high efficacy and cost savings, 17 when used as maintenance therapy (albeit with slightly higher discontinuation rates secondary to adverse events compared with continued therapy on a control standard treatment arm, 3% versus ,1%). [18] [19] [20] Combining PIs and integrase strand transfer inhibitors (InSTIs) offers an alternative, with the advantage of an NRTI-sparing strategy and no deleterious drug-drug interactions, which may be appealing in patients with prolonged exposure to NRTIs, including those with lipoatrophy, fatigue, and/or mild renal insufficiency and especially in those with concurrent NNRTI resistance. 21, 22 The NEAT001/ANRS143 study investigated darunavir/ritonavir combined with raltegravir in 800 ART-naive individuals and found it non-inferior to a standard combination of darunavir/ritonavir/ tenofovir/emtricitabine, based on clinical and/or virological failure at 96 weeks. However, the genetic barrier of the two-drug regimen in this context was lower than the three-drug regimen, with more frequent emergence of resistance in the case of virological failure, particularly in those with high baseline viral loads. 23, 24 In alreadyvirologically-suppressed patients, the SPARE pilot study suggested that raltegravir/darunavir/ritonavir was effective in maintaining viral suppression. 25 However, this combination required twice-daily drug intake, whereas combining boosted darunavir with dolutegravir offers the benefits of once-daily dosing, in addition to simplicity, potency and a high genetic barrier to resistance, since both agents have a high affinity for their target enzymes. 6, 26, 27 Two cohort studies, to date, have been published on the use of dolutegravir/darunavir/ritonavir (DTG/DRV/RTV) in multitreatment-experienced patients. 28, 29 In Canada, Wheeler et al. 28 demonstrated high tolerability and maintenance of viral suppression after a mean of 12.8 (range months in all of 13 HIV patients with primary transmitted thymidine analogue mutation (TAM) resistance, who switched from a complex salvage multidrug regimen to DTG/DRV/RTV. Similarly, in Italy, Capetti et al. 29 followed 130 patients, with a current or past history of virological failure and documented viral resistance to one to five antiretrovirals (ARVs), who switched to DTG/DRV/RTV for simplification or rescue therapy. At the 48 week follow-up, subjects with viral suppression had increased from 60% to 93.9% and the metabolic impact was favourable. 29 In the single-point pharmacokinetics (PK) substudy (32 subjects), the median concentration 24 h post-dose (C 24 ) for darunavir was 3007 (range 678-8053) ng/mL and for dolutegravir was 579 (range 275-5036) ng/mL. Five subjects were taking darunavir (600 mg) twice daily and had C 24 above the threshold for resistant strains [the in vitro protein-adjusted IC 50 (PA-IC 50 ) for PI-resistant viruses, 550 ng/mL].
5, 30 Three participants were taking dolutegravir twice daily (dolutegravir PA-IC 90 for WT HIV is 64 ng/mL; the majority of InSTI single mutations cause ,10-fold changes in dolutegravir susceptibility but twice-daily dosing is recommended in the presence of InSTI resistance-associated mutation patterns). [31] [32] [33] The ongoing DUALIS study is a large, prospective, interventional, randomized, controlled trial set up to assess the safety and efficacy of once-daily dolutegravir with once-daily darunavir/ ritonavir maintenance therapy. Although recruitment is ongoing, an intensive PK substudy over 12 h has been published and describes all steady-state PK parameters for both drugs during coadministration (median C max was 3427 ng/mL for dolutegravir and 6170 ng/mL for darunavir, C 12 was 637 ng/mL for dolutegravir and 1245 ng/mL for darunavir and AUC 0-12 was 26 809 ngÁh/mL for dolutegravir and 49 920 ngÁh/mL for darunavir); C 24 was not measured. 34 PK data for dolutegravir co-administration with darunavir/cobicistat remain, however, very limited. Cobicistat is a newer, approved alternative to ritonavir as a pharmacological booster, which may be preferable in some patients, thanks to a lower potential for drug interactions and lipid disorders than ritonavir. 35, 36 It displays a more selective inhibition of cytochrome P450 (CYP3A) enzymes, a different spectrum of drug transporter inhibition and a lower likelihood for enzymatic induction. Additionally, its molecular properties offer the opportunity for co-formulation with PIs into a fixed-dose combination.
35-37 Dolutegravir C 24 doubled when measured at least 10 days after switching from darunavir/ritonavir to darunavir/cobicistat in a therapeutic drug monitoring survey of HIV-infected subjects (n " 12), 38 in contrast to a 38% decrease seen with twice-daily darunavir/ritonavir in healthy volunteers. 39 No intensive PK data have been published to date on dolutegravir/darunavir/cobicistat co-administration. We therefore aimed to describe the steady-state PK of dolutegravir (50 mg) once daily and of fixed dose darunavir/cobicistat (800/150 mg) once daily, over 24 h when co-administered in healthy volunteers.
Patients and methods

Participants
Eligible participants were male or non-pregnant and non-lactating female healthy volunteers aged between 18 and 65 years with a BMI between 18 and 35 kg/m 2 . Participants were excluded if they had: any significant acute or chronic medical illness; abnormal physical examination, ECG or clinical laboratory determination; positive screens for HIV, hepatitis B or C; current or recent (within 3 months) gastrointestinal disease; clinically relevant alcohol or drug use that the investigator felt would adversely affect compliance with trial procedures; exposure to any investigational drug or placebo within 3 months of the first dose of the study drug; use of any other drugs, including over-the-counter medications and herbal preparations, within 2 weeks of the first dose of the study drug; and previous allergy to any of the constituents of the pharmaceuticals administered during the trial.
Study design
The study design is illustrated in Figure 1 . This was a Phase I, open-label, 57 day, crossover, pilot PK study carried out at the Clinical Trial Unit of the St Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
At screening, participants had a clinical assessment and routine laboratory investigations were performed. After successful screening, eligible participants were randomized to one of two groups. Group 1 received dolutegravir (50 mg) once daily for 14 days followed by a 7 day washout (days [15] [16] [17] [18] [19] [20] [21] . From days 22-35, in the co-administration period, they received dolutegravir (50 mg) once daily plus darunavir/cobicistat (800/ 150 mg) once daily for 14 days, which was followed by a 7 day washout (days [36] [37] [38] [39] [40] [41] [42] and, finally, they finished with a 14 day period of darunavir/ cobicistat (800/150 mg) once daily. Group 2 followed the same structured sequence but started with darunavir/cobicistat (800/150 mg) once daily and concluded with dolutegravir (50 mg) once daily. Subjects were asked to take both dolutegravir and darunavir/cobicistat in the morning, within 15 min of a standard breakfast. The safety and tolerability of study medications were evaluated throughout the trial (on days 7, 28 and 49, PK days and at follow-up) using the NIAID Division of AIDS table for grading the severity of adult and paediatric adverse events to characterize abnormal findings, vital signs, physical examinations and clinical laboratory investigations (published in 2004). Each group underwent intensive PK sampling on study days 14, 35 and 56 to measure plasma concentrations of dolutegravir and/ or darunavir/cobicistat at 0 (pre-dose), 2, 4, 8, 12 and 24 h post-dose. On the PK days, study staff witnessed study medication intake with a standardized breakfast (626 kcal) and 240 mL of water.
PK sample collection
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at each timepoint, immediately inverted several times and then kept on ice or refrigerated until centrifugation. Within 30 min of blood collection, each blood sample was centrifuged for 10 min at 2000 g at 4
C.
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Plasma was then aliquotted into three 2.0 mL tubes (Sarstedt, Germany) and stored at #20 C. Samples were shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The laboratory is Good Clinical Laboratory Practice-accredited and participates in an external quality assurance scheme (KKGT, the Netherlands).
Quantification of plasma dolutegravir, darunavir and cobicistat
Concentrations of dolutegravir, darunavir and cobicistat in plasma were measured using validated HPLC MS/MS as previously described. 40, 41 The lower limits of quantification (LLOQs) were 10 ng/mL for plasma dolutegravir, 15 ng/mL for darunavir and 10 ng/mL for cobicistat. For concentrations below the assay LLOQ, a value of one-half of the quantification limit was used. Accuracy (percentage bias) was 92.5%-96.2% (dolutegravir), 104.1%-104.9% (darunavir) and 95.0%-105.1% (cobicistat) and precision was 2.6%-4.1% (dolutegravir), 4.4%-9.4% (darunavir) and 5.7%-7.3% (cobicistat).
Data analysis
The calculated PK parameters for plasma dolutegravir, darunavir and cobicistat were C 24 , C max and AUC 0-24 . All PK parameters were calculated using actual blood sampling time and non-compartmental modelling techniques (WinNonlin Phoenix, version 6.1; Pharsight, Mountain View, CA, USA). Descriptive statistics, including geometric mean (GM) and 90% CI were calculated for dolutegravir, darunavir and cobicistat plasma PK parameters. Each drug PK parameter during the co-administration period was compared with the unaccompanied drug PK parameter by calculating GM ratios (GMRs) and 90% CI (co-administered/alone).
Inter-individual variability in drug PK parameters was expressed as a percentage coefficient of variation [CV, (SD/mean) % 100].
Since both cobicistat and dolutegravir are associated with a small rise in creatinine through multidrug and toxin extrusion 1 (MATE1) and organic cation transporter 2 (OCT2) transporter inhibition respectively, 42 we evaluated the statistical significance of the changes in creatinine from baseline using the two-sided Wilcoxon signed-rank test for paired samples.
Additionally, as dolutegravir is a substrate of P-glycoprotein 1 (PgP-1) and breast cancer resistant protein (BCRP) efflux transporters, both of which are on the blood-brain barrier and are inhibited by cobicistat, 37 a review of neuropsychiatric adverse events (NPAE) was also carried out.
Statistical power
This is an exploratory study and, as such, no formal sample size calculation was performed. Twenty participants completing the study was deemed appropriate to allow for relevant conclusions, as is standard for PK studies. 43 
Ethics
The study protocol was approved by the Surrey Borders Research Ethics Committee and by the Medicines and Healthcare products Regulatory Agency in the UK. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki (NCT03094507).
Results
Study population
Twenty-five healthy volunteers were screened, 21 attended at baseline and 20 completed all PK phases (11 in group 1; 9 in group 2; and 1 subject withdrew for personal reasons). Median age was 33.5 years (range 24-63), 13 participants were female and median BMI was 27 (range 20-31) kg/m 2 . Thirteen subjects described themselves as Caucasian, six as Black African/Caribbean and one as White and African. Table 1 summarizes the PK parameters for dolutegravir and darunavir/cobicistat when administered alone or together in the coadministration phase, in both groups combined. Figure 2 illustrates the dolutegravir GM plasma concentration-time curves with and without darunavir/cobicistat, in relation to dolutegravir's PA-IC 90 for WT virus (64 ng/mL).
Dolutegravir, darunavir and cobicistat plasma PK
Dolutegravir plasma PK
32,33 Dolutegravir GMR, (dolutegravir with darunavir/cobicistat versus dolutegravir alone) and 90% CI for C max , AUC 0-24 and C 24 were 1.01 (0.92-1.11), 0.95 (0.87-1.04) and 0.9 (0.8-1.0), respectively. No differences were seen between groups 1 and 2. C 24 remained 7-to 32-fold above the dolutegravir PA-IC 90 (64 ng/mL).
32,33
The inter-individual variability in dolutegravir values was between 23% and 40% when administered alone and between 28% and 46% during co-administration with darunavir/cobicistat. 30 in all subjects (except for one participant with a darunavir C 12 of 1428 ng/ mL but C 24 of 185 ng/mL).
Darunavir plasma PK
Safety and tolerability
The studied drugs were well tolerated, with no grade 3 or 4 side effects or laboratory abnormalities. Median (IQR) creatinine was 67 lmol/L (63-71) at baseline, 70 lmol/L (65-74) during darunavir/cobicistat administration, 76 lmol/L (69-81) during dolutegravir administration and 74.5 lmol/L (70-79.5) during co-administration (equivalent to 0.75, 0.79, 0.86 and 0.84 mg/dL, respectively). The difference between baseline and during coadministration was significant (T " 2.5, P , 0.01), which was driven by dolutegravir. However, there was no evidence that adding darunavir/cobicistat to dolutegravir changed median creatinine significantly (P " 0.103), whilst adding dolutegravir to darunavir/cobicistat did (T " 29.5, P , 0.01).
Grade 1-2 drug-related NPAEs were seen in six participants (30%) during dolutegravir monotherapy and in three participants (15%) during darunavir/cobicistat monotherapy. The coadministration of the two drugs did not change the prevalence of drug-related NPAEs, which was 15% during the co-administration period and remained low grade (1-2). The commonest drugrelated NPAEs were a grade 1 headache and sleep disturbances.
Discussion
We characterized the steady-state PK of standard dose dolutegravir co-administered with darunavir/cobicistat over 24 h in healthy volunteers. The changes in dolutegravir PK parameters during coadministration compared with dolutegravir administered alone were minimal. Dolutegravir C 24 decreased by 10%, whilst AUC decreased by 5% and C max remained unchanged. Darunavir concentrations also decreased by less than 10%. Dolutegravir and darunavir concentrations remained many-fold above the PA-IC 90 / PA-EC 90 for WT virus in all participants at all timepoints. In contrast, dolutegravir C 24 had decreased by 38% when co-administered with darunavir boosted by ritonavir (twice daily) in early dolutegravir drug interaction studies, [C max #11% and AUC #22%; participants received multi-dose dolutegravir (30 mg), administered with food]. 39 Our results suggest that dolutegravir and darunavir/cobicistat can be co-prescribed safely in the treatment of HIV-1 infection, without requiring any adjustment to the dosages currently recommended in guidelines, which are 800/150 mg once daily for darunavir/cobicistat and 50 mg once daily for dolutegravir, except in patients harbouring darunavir and/or InSTI resistanceassociated mutations where darunavir/cobicistat (600/150 mg) and/or dolutegravir (50 mg) twice-daily dosing is recommended, in order to optimize drug exposure. 9, 10, [44] [45] [46] [47] [48] Our findings are consistent with those of Gervasoni et al., 38 who reported a doubling of dolutegravir C 24 in HIV patients switching from darunavir/ritonavir to darunavir/cobicistat. Dolutegravir is Elliot et al. Dolutegravir and darunavir/cobicistat pharmacokinetics JAC primarily metabolized by UDP-glucuronosyltransferase-1A1 (UGT1A1) and is only a minor substrate for cytochrome P450 (CYP) 3A4. 49 Whilst both cobicistat and ritonavir are potent CYP3A4 inhibitors, unlike ritonavir, cobicistat does not induce glucuronidation (or any CYP enzymes), which is likely to explain the difference in effect seen between the two pharmacological boosters. [35] [36] [37] A lack of inhibition (by both ritonavir and cobicistat) of UGT1A1, 1A3, 1A6, 1A9, 2B4 and 2B7 was also recently demonstrated in vitro, meaning that, in agreement with our results, cobicistat has a lack of effect overall on UGT. 50 Interestingly, Gervasoni et al. commented on the possibility that their observed surge in dolutegravir concentrations when ritonavir was switched to cobicistat may be driven, at least in part, by a higher degree of inhibition of cobicistat on intestinal efflux transporters (PgP and BCRP), leading to increased dolutegravir absorption. 38, 51 However, in vitro, cobicistat appears to have a significantly higher IC 50 for PgP and BCRP inhibition than ritonavir and we did not see a rise in dolutegravir C max when darunavir/cobicistat was added to dolutegravir, which would suggest that, on the contrary, the inhibitory effect of cobicistat on these transporters is limited at the most. 37 Dolutegravir does not induce or inhibit CYP enzymes, 32 therefore effects on darunavir and cobicistat (which are mainly metabolized by CYP3A4) were not expected during co-administration with dolutegravir.
Interestingly, the PK parameters of dolutegravir in our study were, overall, lower than seen in the study by Min et al. 33 (also healthy volunteers, n " 8, food intake not specified) when administered alone and lower than in the Gervasoni et al. 38 study when co-administered with darunavir/cobicistat, highlighting the importance of describing intra-individual effects in drug interaction studies.
Serum creatinine concentrations significantly increased from baseline during dolutegravir administration, but no significant increment was recorded when darunavir/cobicistat was added to dolutegravir, which is consistent with previous observations that administration may not result in additive renal toxicity, at least in the short term. 38, 52 The commonest NPAEs seen were mild headache and sleep disturbances, particularly with dolutegravir (30%). Co-administration of dolutegravir with darunavir/cobicistat did not increase the prevalence of NPAEs; however, our study was not powered for a toxicodynamic analysis.
There are limitations in this study. Subjects were healthy volunteers and conclusions cannot be fully extrapolated to HIV-infected participants. In licensing trials, dolutegravir concentrations appeared generally lower in HIV-infected participants than in healthy volunteers. 53 Indeed, discrepancies in ARV drug PK between healthy volunteers and PLWH have previously been described (particularly for the PIs to date). 54 It is thought that such differences are related to physiological variability in several parameters between the two populations, including enzyme activity and a-1-acid glycoprotein expression. 54 Similarly, pharmacodynamics deductions cannot be drawn; however, the two cohort studies described above have reported good efficacy of dolutegravir and boosted-darunavir dual therapy in small groups of treatmentexperienced HIV-infected individuals 28, 29 and the DUALIS study will provide further insight into its efficacy in a large ARV-naive population. 34 The strengths of our study lie in its prospective, controlled and crossover design, which allowed an analysis of intra-individual effects. Additionally, the study population was appropriately diverse in gender, ethnicity and age.
In conclusion, we investigated the intra-individual variance in dolutegravir and darunavir/cobicistat PK parameters when administered together compared with alone. Our results suggest that no dose adjustment is required for either agent and that this combination can be prescribed safely in the treatment of HIV-1, at currently recommended doses, including in treatment-experienced patients harbouring certain resistance patterns, in whom twicedaily dosing remains recommended. 44, 46, 47 
